Actinium Pharmaceuticals ... (ATNM)
1.36
0.16 (13.33%)
At close: Apr 22, 2025, 3:59 PM
1.35
-1.10%
After-hours: Apr 22, 2025, 06:29 PM EDT
13.33% (1D)
| Bid | 1.18 |
| Market Cap | 42.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.24M |
| EPS (ttm) | -1.27 |
| PE Ratio (ttm) | -1.07 |
| Forward PE | -1.21 |
| Analyst | Buy |
| Ask | 1.43 |
| Volume | 543,098 |
| Avg. Volume (20D) | 600,288 |
| Open | 1.25 |
| Previous Close | 1.20 |
| Day's Range | 1.23 - 1.39 |
| 52-Week Range | 1.03 - 10.24 |
| Beta | -0.27 |
About ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 27, 2012
Employees 37
Stock Exchange AMEX
Ticker Symbol ATNM
Website https://www.actiniumpharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ATNM stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 266.30% from the latest price.
Stock Forecasts4 weeks ago
+18.35%
Actinium Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
1 month ago
+16.53%
Actinium Pharmaceuticals shares are trading higher after the company announced it entered a research collaboration with Memorial Sloan Kettering for clinical expansion of Actimab-A's backbone therapy strategy.
